Yearbook - Edition 20jj

This report provides a statistical review of the U.S. manufacturing industry. There are three aspects of U.S. manufacturing that are considered: (1) how the U.S. industry compares to other countries, (2) the trends in the domestic industry, and (3) the industry trends compared to those in other countries.

Gene therapies (GTx) are a significant breakthrough in the pharmaceutical industry, with the potential to treat genetic disorders by modifying defective genetic material. Luxturna has already restored sight in some patients, highlighting the therapies’ effectiveness. However, these treatments come at a high cost, up to USD 3.5 million per dose for Hemgenix, a hemophilia B infusion. Manufacturing gene therapies requires entirely new modalities that lack the efficiency and cost savings of traditional pharmaceutical production. Additionally, production speeds are currently slow. Despite these challenges, efforts are underway to exploit the technology and reduce costs. This article provides a market overview of GTx, discusses manufacturing challenges, and explores promising technologies to overcome them.

Exports from developing Asia weakened in the first quarter of 2023 as global demand slowed. However, consumption and investment are forecast to boost aggregate regional growth to 4.8% in 2023, as earlier forecast, with the projection for 2024 revised down only marginally to 4.7%.

Exports from developing Asia weakened in the first quarter of 2023 as global demand slowed. However, consumption and investment are forecast to boost aggregate regional growth to 4.8% in 2023, as earlier forecast, with the projection for 2024 revised down only marginally to 4.7%.

This publication outlines why post-disaster needs assessments (PDNA) should provide comprehensive details of the economic and social impacts of disasters on countries to swiftly mobilize resources and support resilient recovery.

Supply constraints; manufacturing; output; inflation